Macular Degeneration clinical trials at UC Davis
2 research studies open to eligible people
Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
“We hope to learn more about the safety and feasibility of using your own (autologous) stem cells extracted from your bone marrow.”
open to eligible people ages 18-100
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
Sacramento, California
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
“Interested in a potential new treatment? Help us with wet AMD research!”
open to eligible people ages 50 years and up
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Los Angeles, California and other locations
Our lead scientists for Macular Degeneration research studies include Susanna s Park, MD PhD.
Last updated: